Clinical and histopathological distinction between the inherited versus acquired bone marrow failure or myelodysplastic syndromes is challenging. The identification of inherited bone marrow failure/ myelodysplastic syndromes is critical to inform appropriate clinical management. To investigate whether a subset of pediatric and young adults undergoing transplant for aplastic anemia or myelodysplastic syndrome have germline mutations in bone marrow failure/myelodysplastic syndrome genes, we performed a targeted genetic screen of samples obtained between 1990-2012 from children and young adults with aplastic anemia or myelodysplastic syndrome transplanted at the Fred Hutchinson Cancer Research Center. Mutations in inherited bone marrow failure/myelodysplastic syndrome genes were found in 5.1%(5/98) of aplastic anemia patients and 13.6%(15/110) of myelodysplastic syndrome patients. While the majority of mutations were constitutional, a RUNX1 mutation present in the peripheral blood at a fifty-percent variant allele fraction was confirmed to be somatically acquired in one myelodysplastic syndrome patient. This highlights the importance of distinguishing germline versus somatic mutations by sequencing DNA from a second tissue or from parents. Pathologic mutations were present in DKC1, MPL, and TP53 among the aplastic anemia cohort, and in FANCA, GATA2, MPL, RTEL1, RUNX1, SBDS, TERT, TINF2, and TP53 among the myelodysplastic syndrome cohort. Family history or physical examination failed to reliably predict the presence of germline mutations. This study shows that while any single specific bone marrow failure/myelodysplastic syndrome genetic disorder is rare, screening for these disorders in aggregate identifies a significant subset of patients with inherited bone marrow failure/myelodysplastic syndrome.
Introduction
The overlap in clinical presentation and bone marrow features of inherited and acquired bone marrow failure syndromes and pediatric myelodysplastic syndromes (MDS) can pose a significant diagnostic challenge. Idiopathic acquired aplastic anemia (AA) is typically a diagnosis of exclusion after inherited disorders, acquired MDS, infections, metabolic diseases, or nutritional deficiencies have been ruled out. Childhood MDS is emerging as clinically and biologically distinct from MDS in the elderly 1, 2 . Importantly, and in contrast to MDS in the elderly, the majority of cases of refractory cytopenia of childhood, the most common subtype of pediatric MDS, are hypocellular with a normal karyotype 3 . If MDS-related cytogenetic abnormalities are absent, the distinction between refractory cytopenia of childhood and AA or an inherited bone marrow failure or myelodysplastic predisposition syndrome (iBMF/MDS) is challenging. Furthermore, patients with iBMF/MDS can initially present with MDS or acute leukemia, obscuring diagnosis of their underlying disorder.
The clinical and histopathological distinction between germline genetic versus acquired disorders has important therapeutic implications. The major treatments for AA currently consist of either hematopoietic stem cell transplant (HSCT) or immunosuppressive therapy (IST) with antithymocyte globulin (ATG) and cyclosporine. Choice of therapy is largely based on patient age, availability of a matched sibling donor, and co-morbidities. The success of IST is limited by lack of response in approximately 30% of patients, relapse in 30% of patients who initially responded, and clonal evolution in 10-20% of patients 4 . Progressive improvement in outcomes of matched unrelated donor transplants raises the question of whether this should be considered in lieu of IST as first-line therapy for a subset of patients. In contrast, patients with inherited bone marrow failure syndromes generally have poor or transient responses to IST [5] [6] [7] . In childhood MDS, the indications for HSCT are currently based on the severity of cytopenias, the degree of marrow dysplasia 8 , the peripheral blood and marrow blast percentages, and cytogenetic aberrations. In addition to informing the timing and indication for HSCT, accurate distinction of these entities informs HSCT approaches. Many iBMF/MDS are associated with excessive transplant regimen-related toxicities and may require specialized reduced intensity conditioning regimens for optimal outcomes 9, 10 . Additionally, the careful evaluation of a related stem cell donor is critical in the context of a familial genetic disease.
The objectives of this study were to investigate whether pediatric and young adult patients undergoing transplant for AA and MDS harbored pathogenic constitutional mutations in iBMF/MDS genes and to examine whether family history or physical findings were associated with mutation status. We employed a multiplexed targeted capture gene panel of known inherited and acquired BMF/MDS genes coupled with next generation sequencing to query 208 pediatric and young adult patients referred for HSCT for AA and MDS for mutations in known iBMF/MDS genes. Genomics. Targeted gene capture and massively parallel sequencing were performed as previously described using a capture assay targeting mutations in known inherited and acquired bone marrow failure and MDS genes 11 . The genes included on the targeted capture panel are listed in Supplementary Table 1 . Reads were aligned to the human reference genome (hg19) using the Burrows-Wheeler aligner 12 and single nucleotide and small insertion-deletion variants called with GATK, using best practice guidelines, as previously described 13 . Alignment to the whole genome facilitated exclusion of variants that fell in pseudogenes. Copy number variants (CNVs) were identified as previously described 14 .
Methods

Subjects
Mutations were identified by a variant allele fraction consistent with heterozygosity (0.3-0.7). Somatic mutations defined by variant allele fraction of less than 30% were excluded from the analysis as were recessive mutations inconsistent with a Mendelian inheritance pattern.
Variants were classified as pathogenic by predicted effect on protein function, as previously described 15, 16 . Pathogenic variants were validated by Sanger sequencing. Compound heterozygous variants were confirmed to be in trans by subcloning and Sanger sequencing. Variants were confirmed as constitutional by sequencing DNA isolated from paraffin embedded biopsy samples of skin, lip, or gastrointestinal tissue or by chromosome fragility testing of patient-derived lymphoblasts, performed as previously described 17 . See the Online Supplementary Methods section for more detailed descriptions.
Results
Aplastic anemia patient characteristics
The study group transplanted for AA included 53 pediatric (≤18 years-old) and 45 young adult (>18 years-old) patients (range 1-40 years-old). Family history of a 1 st or 2 nd degree relative with malignancy or cytopenias was present in 40% (39/98) of patients. Physical anomalies were noted in 11% (11/98) of patients. An HLA-matched sibling transplant was performed for 38 patients, 6 of whom had received IST prior to transplant. 54 patients received alternative donor HSCT due to refractory or relapsed disease following IST and the remaining 6 patients received alternative donor HSCT after failing other medical therapies (Supplementary Table 2 ).
Myelodysplastic syndrome patient characteristics
Among the 135 patients transplanted for MDS, 25 patients with a current or antecedent history of a myeloproliferative disorder were excluded from further analyses, leaving a total of 110 patients for study (Supplementary Table 3 ). The final study group included 46 pediatric (≤18 years-old) and 64 young adult (>18 years-old) patients (range 1-46 years-old). Family history of a 1 st or 2 nd degree relative with malignancy or cytopenias was present in 52% (57/110) of patients. Physical anomalies were noted in 24% (26/110) of patients.
Analysis of iBMF/MDS genes
Given the diagnostic challenge of discriminating between inherited versus acquired BMF/MDS, we hypothesized that a subset of pediatric and young adult patients who underwent HSCT at our center for AA or MDS had cryptic inherited disorders. This hypothesis was addressed using a targeted capture panel coupled to high throughput next generation sequencing of genes known to contribute to inherited and acquired marrow failure and MDS (Supplementary Table  1) 11 . For all samples evaluated, median coverage across the 712 kb targeted region was 444X, with 99.4% of bases having >50X coverage and 99.6% of bases having >10X coverage. This depth of coverage enabled identification of point mutations, small indels, and copy number variants spanning three exons
Aplastic anemia genetics
Pathologic constitutional mutations in known iBMF/MDS genes were identified in 5 of 98 (5.1%) pediatric and young adult patients with AA (Table 1 and Supplementary Table 4 ). Hemizygous mutations in DKC1 were identified in AA3 (T66A) and AA45 (c.-142 C>G). Compound heterozygous and homozygous mutations in MPL were identified in AA25 (R102P and W515X) and AA37 (P394S), respectively and a heterozygous mutation in TP53 was identified in AA79 (R196Q). Constitutional mutations in DKC1, MPL, and TP53 cause X-linked dyskeratosis congenita (DC), autosomal recessive congenital amegakaryocytic thrombocytopenia, and the autosomal dominant familial cancer predisposition syndrome, Li Fraumeni, respectively 7 . Germline TP53 mutations carry an increased risk of developing AML and MDS [18] [19] [20] . See the Online Supplementary Results section for more detailed descriptions of the genetics.
Aplastic anemia genotype-phenotype analysis
Among the five AA patients in whom constitutional mutations in known inherited BMF/MDS genes were found, two patients were clinically suspected to have a constitutional disorder prior to their initial HSCT. Patient AA3 was diagnosed with DC at 10 years-old based on physical exam findings seen in DC, namely, nail dystrophy and a hyperpigmented macule, and a family history of 4 brothers with clinical DC and several family members with early cancers. AA25 presented with an intracranial hemorrhage and severe thrombocytopenia at birth and was diagnosed with congenital amegakaryocytic thrombocytopenia which was genetically confirmed. Of the five patients with constitutional mutations, three received an upfront transplant from an HLA-matched sibling donor. One patient (AA37) received IST prior to an alternative donor transplant and a second patient, AA25, received G-CSF and erythropoietin prior to undergoing an alternative donor transplant. Patient AA3 died of colon cancer 21 months post-transplant (Table 1 ). Colon cancer is a known complication of DC 21 .
A negative family history did not reliably distinguish those patients lacking mutations in inherited BMF/MDS genes ( Table 2 ). Absence of physical anomalies also failed to distinguish patients with acquired versus germline genetic forms of AA ( Table 2 ).
The presence of a paroxysmal nocturnal hemoglobinuria (PNH) clone was assessed by flow cytometry using 4-color or 6-color flow cytometry of marrow or peripheral blood, or, in one patient, by Ham test. A PNH clone was detected in 5 of 50 patients tested (10%), none of whom harbored a constitutional mutation in an inherited BMF/MDS gene.
Myelodysplastic syndrome genetics
Pathologic mutations in known inherited BMF/MDS genes were identified in 15 out of 110 (13.6%) pediatric and young adult patients with MDS (Table 3 and Supplementary Table 4 
Myelodysplastic syndrome genotype-phenotype analysis
Among the fourteen MDS patients in whom constitutional mutations in known inherited BMF/MDS genes were found, only three patients were clinically suspected to have a constitutional disorder prior to their initial HSCT. HIP05737 was diagnosed with congenital amegakaryocytic thrombocytopenia during her pre-transplant evaluation and HIP02099 was suspected to have Shwachman-Diamond Syndrome pre-transplant based on a history of marrow failure and pancreatic insufficiency presenting in a 3.5 month-old boy (without genetic confirmation of the diagnosis). HIP21264 was a member of a known Li-Fraumeni family whose TP53 mutation was formerly defined.
Additionally, while patients with constitutional mutations presented for HSCT at a younger age than those lacking mutations (median age 12.1 years-old vs. 31.2 years-old), the absence of a prior personal history of cancer, family history of a 1 st or 2 nd degree relative with cancer or a related phenotype, or the presence of physical anomalies did not reliably rule out mutations in inherited BMF/MDS genes ( Table 4 ). Only two of the five patients carrying heterozygous pathogenic mutations in GATA2 had a family history suspicious of an inherited disorder (HIP08919 and HIP18921, Table 3 ).
Standard bone marrow transplant conditioning regimens used for MDS can cause excessive and life-threatening toxicities in patients with certain inherited BMF/MDS 7 . Some patients, for example those with DC 9 , may also face higher risk of graft failure. The clinical course of HIP12286, who carried compound heterozygous deleterious mutations in FANCA, illustrates this issue. She initially presented at age 20 years-old (five years prior to transplant) with epistaxis and was found to have mild thrombocytopenia and macrocytosis in the context of a hypocellular marrow for age. Her family history was unremarkable and she lacked physical or structural anomalies suggestive of an inherited BMF/MDS. She developed progressive cytopenias and monosomy 7 and received an URD BMT with busulfan and cyclophosphamide conditioning. She died 23 days post-transplant of severe transplant-related toxicity, including whole body blistering and a desquamative rash requiring surgical debridement, hypoxic respiratory failure with evidence of diffuse alveolar damage, and severe diarrhea with endoscopic findings of necrotic gastric mucosa. Patients with Fanconi anemia are exquisitely sensitive to genotoxic agents (e.g., alkylators and ionizing radiation) and face potentially severe regimen-related toxicity and high mortality rates with standard conditioning regimens containing these agents.
HIP02696, who carried compound heterozygous mutations in RTEL1, provides a second example of transplant outcomes in a patient with an unrecognized inherited BMF/MDS at the time of their initial transplant, specifically, Hoyeraal-Hreidarsson syndrome. His transplant courses were marked by recurrent graft failure -initially after a nonmyeloablative HLA-matched URD transplant utilizing a fludarabine and 200cGy TBI preparative regimen and again after a second nonmyeloablative PBSCT from the same donor utilizing a fludarabine, ATG, and cyclophosphamide preparative regimen. He ultimately engrafted after infusion of marrow hematopoietic stem cells without conditioning from the same original donor and died 95 months post his original transplant from multi-organ system failure. Of note, among the six patients with damaging mutations in dyskeratosis congenita genes in this study (Supplementary Table 5 ), pulmonary complications developed in one of these six patients at ~6 months post transplant.
Discussion
Inherited bone marrow failure syndromes, idiopathic acquired aplastic anemia, and hypoplastic MDS share significant overlap in clinical presentation and bone marrow findings, which often pose a diagnostic challenge. In the present study we determined whether pediatric and young adults referred to our center for HSCT for either AA or MDS harbor mutations in inherited bone marrow failure and MDS genes. We found that 5.1% of AA and 13.6% of MDS patients carried mutations in known inherited BMF/MDS genes.
Prior studies have sought to define this incidence by analyzing single genes or small sets of genes. Genetic analyses were confined to single genes or limited gene sets. Yamaguchi H. et al. screened patients with apparently acquired aplastic anemia for mutations in TERT, DKC1, NHP2, and NOP10, and reported heterozygous mutations in TERT in ~3.4% (7/205) of patients with AA unresponsive to IST 5 . Their study included patients ages 2-83 years-old with a median age of 34 years-old, which is older than our series of AA (median age 18 years-old). A second study of TERC mutations in 210 patients with bone marrow failure syndromes, including 150 AA and 55 MDS patients, identified heterozygous mutations in only 3/210 (1.4%) cases 6 . Field J. et al. reported only two TERC mutations in 284 blood samples obtained from pediatric patients with AA (n=109), MDS (n=137), or juvenile myelomonocytic leukemia (n=38) under 18-years of age who underwent a stem cell transplant for marrow failure from the National Donor Marrow Program Research Sample Repository 24 . The incidence of inherited BMF/MDS appeared to be low based on these studies. A recent German study, limited to GATA2 sequencing, demonstrated a 7% (28/426) incidence of germline GATA2 mutations among children and adolescents with de novo MDS 25 .
Our study here demonstrated that by expanding the genetic screen to include a large set of inherited BMF/MDS genes, a significant subset of patients carried germline mutations. These results extend a previous study where we found that 11% (8/71) of patients, primarily from the pediatric age group, harbored germline BMF/MDS gene mutations 11 . While the majority of mutations identified in our previous study affected the GATA2 gene, our current study identified mutations in a wide variety of genes. A subsequent study utilized a targeted next generation sequencing panel of 72 inherited bone marrow failure genes to screen ten patients with severe aplastic anemia unresponsive to immunosuppressive therapy 26 . Mutations were found in three of the ten patients (30%). One patient carried compound heterozygous mutations in RTEL1, one patient had a heterozygous TERT mutation, and a third patient had a heterozygous mutation in microtubule-associated serine/threonine kinase like (MASTL), which had previously been reported in autosomal dominant thrombocytopenia. This group additionally identified mutations involving CXCR4, GATA2, G6PC3, MAST, MYH9, RPL5, RTEL1, TERT, TERC, TINF2, or WAS in 18.1% (15/83) of patients with unclassified inherited bone marrow failure syndromes 26 . These studies demonstrate that while mutations in any single gene are rare, mutations in BMF/MDS genes as a group are found in a significant subset of patients.
The results of this study underscore the limitations of relying on clinical stigmata or family history to identify patients with an underlying constitutional disorder. Only 2 of the 5 AA patients with mutations in an inherited BMF/MDS gene had a physical anomaly and only 1 patient had a family history of cancer or a related phenotype. Among the MDS cohort, only 3 of the 14 patients with mutations in an inherited BMF/MDS gene had a physical anomaly and while patients with mutations were more likely to have a positive family history of cancer or a related phenotype than those patients without mutations, the absence of a family history did not exclude the possibility of a mutation. While the retrospective design of this study limits the available physical anomaly and family history data to that captured in the medical record, and thus warrants further studies to confirm the generalizability of our findings, our conclusions are consistent with other published work. Our earlier study identified mutations in 8 of 71 (11%) pediatric and adult (<40 years-old at presentation or with a family history of BMF/MDS regardless of age) patients with idiopathic bone marrow failure, where all eight patients lacked classical clinical stigmata of these syndromes and only four had a suggestive family history despite extensive longitudinal evaluation 11 . Our study both complements and expands on a recent large study of 1,120 pediatric cancer patients which found that 8.5% of patients had germline mutations in inherited cancer predisposition genes and more than half of the children with germline mutations lacked any family history of cancer 27 .
Our study also highlights the importance of recognizing inherited BMF/MDS to inform appropriate medical care. One of the five AA patients with mutations in inherited BMF/MDS genes received IST without response. Patients with inherited BMF/MDS respond poorly or transiently to IST and are at increased risk of relapse and clonal evolution with reduced survival 28 . Additionally, sibling mutation status would inform transplant donor choice. For relapsed MDS post-sibling donor transplant, it would be informative to determine whether relapsed MDS involved donor vs. recipient-derived cells. Published reports suggest a high transplant-related mortality and organ toxicity in patients with certain inherited BMF/MDS transplanted using standard preparatory regimens for aplastic anemia or MDS 7, 9, 10 . The severe and immediate post-transplant complications observed in the Fanconi anemia, subtype A patient in this study (HIP12866) provides an informative example of this risk. Additionally, DC appears to be associated with early and late graft failure and pulmonary toxicity with standard transplant preparatory regimens 9 , which was observed in this series (HIP02696 and HIP05477, respectively).
Given the increased risks of hematologic and solid tumors associated with inherited BMF/MDS, a clinical surveillance protocol for patients has the potential to improve outcomes in individuals and affected family members of genetically defined probands. These patients may face particularly high risk of tumors post-HSCT.
One of the challenges in genetic studies is the ascertainment of pathogenicity for a given variant. As our understanding evolves, reassessment of previously described variants is continually warranted. For example, we observed the TERT c.C1234T (H412Y) variant in a 10 year-old girl with MDS and a 2 year-old boy and 27 year-old man with AA and additionally have observed this in 4 other patients among the 1042 patients with marrow failure or MDS sequenced on our targeted gene sequencing platform. This missense mutation affects an amino acid that is not highly conserved across species and is reported in 121 alleles (among a total of 19080) on the Exome Aggregation Consortium, including two homozygous individuals (ExAC, Cambridge, MA). The lack of amino acid conservation across species and frequent observation in our laboratory and on ExAC suggest that while the variant reduces telomerase activity in vitro 5 , it might be clinically benign in humans in the heterozygous state. Du HY et al. reported a family in which the proband had clinical DC, very short telomere lengths, and a homozygous TERT P704S mutation resulting in reduced telomerase activity. The proband's father carried compound heterozygous P704S and H412Y TERT mutations and very short telomere lengths. The proband's mother had neither clinical evidence of DC nor very short telomere lengths in peripheral blood mononuclear cells and was heterozygous for the P704S allele. Since both mutations are hypomorphic alleles, impairing but not eliminating telomerase activity 29 , these data suggested that hypomorphic TERT mutations might contribute to disease when present together in the compound heterozygous or homozygous state. Further studies are warranted to clarify whether a single heterozygous TERT H412Y variant is pathogenic in humans.
Several limitations of this study must be considered. While the rarity of AA and MDS in children and young adults precluded a prospective study, the retrospective study design limits the available clinical history. Further studies with comprehensive clinical data, including a detailed family history and physical exam findings with attention to subtle features associated with marrow failure, to accompany the genetic evaluation are warranted. The frequency of germline mutations in our study group may be underestimated since our variant pipeline filtered out mutations with a variant allele fraction of less than 0.30 that might eliminate patients with somatic mosaicism 27 .
In current practice, testing for an underlying genetic disorder is most commonly considered in pediatric and young adult patients presenting with bone marrow failure. Genetic testing is rarely pursued in pediatric and young adult patients presenting with MDS. While screening BMF/MDS patients for mutations in a single gene or small set of genes reveals rare cases of germline mutations, we find that comprehensive screening of BMF/MDS genes in aggregate reveals a significant subset of previously unrecognized patients. As we restricted our AA analysis to those patients with severe aplastic anemia requiring HSCT, it will be interesting to query the frequency of constitutional mutations in inherited BMF/MDS genes among patients diagnosed with moderate aplastic anemia. Since many of these disorders require specialized consideration of familial donor evaluation and counseling, reduced intensity conditioning regimen, and surveillance for disease-specific extrahematopoietic complications, diagnosis prior to transplant is critical. Our findings suggest that genetic screening to evaluate the inherited bone marrow failure and MDS genes collectively should be considered in pediatric and young adults presenting with AA and MDS. 10% (9) 40% (2) Three-year overall survival post-HSCT, percent (n) 76% (71) 80% (4) Cancers post HSCT, excluding relapsed disease, percent (n) 10% (9) 20% (1) 1 5 24% (23) 21% ( (c.G587A [p.R196Q]). This mutation has previously been reported in solid tumors. The mutation is located in the DNA binding domain of TP53 and impairs transcriptional transactivation 8 .
Myelodysplastic syndrome genetics
Compound heterozygous mutations in FANCA were identified in HIP12286 (c.C1645T [p.Q549X] and c.3349-1G>A). FANCA p.Q549X has been previously reported and confirmed to be pathologic by complementation assay 9 . FANCA c.3349-1G>A has also been previously reported and occurs at a highly conserved nucleotide resulting in disruption of a canonical splice acceptor site in exon 34 10 . Increased mitomycin C and diepoxybutane chromosomal breakage of patient-derived lymphoblasts confirmed the diagnosis of Fanconi anemia.
HIP08919 carried a heterozygous frameshift mutation in GATA2 (c.302delG [p.G101Afs*]). HIP17707 carried a heterozygous GATA2 mutation predicted to affect the exon 4 splice donor site (c.1017+2T>C). This mutation is novel; however a de novo GATA2 c.1017+2T>G mutation at this nucleotide position has been reported in a man with MDS characterized by monocytopenia and warts 11 . HIP18921 carried a nonsense mutation that truncates the protein in the first zinc finger domain (GATA2 c.988C>T [p.R330X]) which has previously been reported in patients with GATA2 deficiency 12, 13 . HIP18952 carried a missense mutation (GATA2 c.1061C>T [p.T354M]), which was previously reported in several families with familial AML/MDS and shown to encode a mutant GATA2 with reduced DNA binding affinity which also impaired wild-type GATA2 function in a dominant-negative fashion 14 . HIP20476 carried a missense mutation in GATA2 which altered a highly-conserved residue in the second zinc finger domain previously reported in a 26 year-old woman with MDS and a history of atypical mycobacterial infections (GATA2 c.1081C>T [p.R361C]) 15 .
HIP05737 carried compound heterozygous mutations in MPL. Biallelic constitutional mutations in MPL cause congenital amegakaryocytic thrombocytopenia (CAMT) 16 . This patient and her family have been previously reported and illustrate the phenotypic heterogeneity of inherited marrow failure that complicates the accurate diagnosis of specific syndromes based on clinical findings alone 17 . The proband's clinical history is notable for a nonclassical presentation of CAMT at a late age (11 years-old) with pancytopenia and marrow hypocellularity concerning for AA. Her seemingly healthy two brothers were evaluated as potential stem cell donors and found to have thrombocytopenia and also carried both mutations in trans. One allele (c.235_236del [p.L79Efs*]) causes a frameshift in exon 3 resulting in premature polypeptide termination and a lack of cell surface expression of the receptor. The second mutation (c.393+5G>C) disrupts a conserved exon 3-intron 3 splice donor site causing diminished MPL expression.
Four patients carried mutations in genes affecting telomere maintenance. Two patients carried compound heterozygous mutations in RTEL1, which encodes a helicase essential for telomere maintenance and regulation of homologous recombination. Several recent reports have described heterozygous, compound heterozygous, and homozygous RTEL1 mutations in a severe form of Dyskeratosis congenita called Hoyeraal-Hreidarsson syndrome (HHS) [18] [19] [20] [21] . Additionally, heterozygous germline mutations in RTEL1 are reported in familial interstitial pneumonia and these cases exhibit short telomere lengths in peripheral blood mononuclear cells 22 . HIP17561 carried a novel missense mutation affecting a highly conserved residue in a helicase domain (RTEL1 c.347A>G [p.H116R]) and a novel missense mutation (RTEL1 c.167C>T [p.T56M]) that did not affect any known functional domain; however, a methionine at that position might provide an alternative start codon for translation. The PolyPhen2 and Gerp scores for these two variants are 1.0/4.84 and 1.0/4.94, respectively suggesting the mutations are damaging. HIP02696 harbored a missense mutation in a helicase domain of RTEL1 (RTEL1 c.1476G>T [p.M492I]) that has been previously reported, in the compound heterozygous state with RTEL1 c.2992C>T (p.R998X) 21, 23 . HIP02696 carried a second missense mutation (RTEL1 c.3791G>A [R1264H]) in the C-terminus of the protein, distal to the helicase domain and previously reported as a germline homozygous mutation in two families with HHS 19 . We were unable to confirm definitively that this variant was constitutional as we had discordant results from Sanger sequencing of DNA isolated from skin and GI tissues. The available clinical histories of these two patients with compound heterozygous RTEL1 mutations were strikingly different. HIP02696 was an only child with a family history notable for a paternal grandmother and great-aunt with chronic lymphocytic leukemia. His clinical history was classic for HHS and included a history of intrauterine growth retardation, oligohydramnios, reversal of placental flows and decreased fetal activity which prompted cesarean-section delivery at 30 weeks gestation and brief oxygen support at delivery. He had microcephaly, cerebellar hypoplasia, hypogonadism and was characterized as having axial hypotonia and postural difficulties that caused difficulty feeding early in life. Around age 18 months, he was found to have mild peripheral blood cytopenias and marrow hypocellularity and went on to develop progressive marrow failure and ultimately underwent a nonmyeloablative unrelated donor peripheral blood HSCT at 2 years of age complicated by graft failure. He underwent a second nonmyeloablative unrelated donor peripheral blood HSCT from the same donor two months after his first transplant that also culminated in graft failure and ultimately engrafted after transplantation without conditioning of bone marrow hematopoietic stem cells from the same donor. He passed away approximately 98 months after his initial transplant at age 10 years of multi-organ system failure presumed secondary to infectious complications in a chronically immunosuppressed patient. HIP17561 initially presented at age 33 years with easy bruising, thrombocytopenia (platelets 11,000/uL) and idiopathic macrocytosis. He was treated with steroids and intravenous immunoglobulin for presumed immune thrombocytopenic purpura without response and was subsequently found to have a hypocellular marrow with dysplastic changes. He underwent an HLA-matched sibling HSCT with peripheral blood stem cells at age 34 years with a myeloablative cyclophosphamide and ATG conditioning regimen. Approximately 12 years posttransplant, he died of liver failure, which was presumed alcohol-related. This outcome is intriguing given the association of liver disease with telomeropathies. His family history was notable for a mother with thrombocytopenia attributed to immune thrombocytopenic purpura that reportedly responded to splenectomy. Telomere length testing was not available for either of these patients.
HIP02099 carried compound heterozygous mutations in SBDS (c.A184T [p.K62X] and c.258+2T>C). Mutations in SBDS cause Shwachman-Diamond syndrome (SDS), an autosomal recessive disorder with clinical features that include pancreatic exocrine dysfunction, hematological dysfunction, skeletal abnormalities, and leukemia predisposition. The missense mutation is located in exon 2 of the SBDS gene and introduces a stop codon at amino acid 62. The intron 2 splice site mutation disrupts a donor splice site leading to a frameshift that prematurely terminates translation of the SBDS protein 24 . The SBDS mutations in HIP02099 remained experimentally unconfirmed as constitutional. The presence of an adjacent pseudogene sharing 97% homology to the SBDS gene precluded confirmatory sequencing of paraffin embedded tissues due to the small quantities of short fragmented DNA available from paraffin embedded tissue samples; additionally, the small quantity of DNA isolated precluded distinguishing pseudogene from gene using our targeted gene capture and NGS panel 25 . However, HIP02099's clinical history of cytopenias and steatorrhea requiring pancreatic enzyme replacement supported the diagnosis of Shwachman-Diamond Syndrome.
HIP02687 carried a heterozygous missense mutation in TERT (c.C2110T [P704S]), which has been previously reported in 2 unrelated patients. This variant was heterozygous in one patient with a history of recurrent AA after ATG and cyclosporine therapy 26 and homozygous in another patient who presented with mucocutaneous features classic for DC. Both patients had reduced telomere length in peripheral blood mononuclear cells and reduced telomerase activity 27 .
HIP05477 carried a heterozygous missense mutation in TINF2 (c. HIP21264 carried a heterozygous deletion-frameshift mutation in TP53 (c.626delGA [R209Ffs*]). HIP21264 initially presented at age 15 years-old with a rib osteosarcoma and received alkylator-based chemotherapy. Six years-later she was diagnosed with therapy-related MDS and ultimately underwent an URD peripheral blood HSCT around age 23 years with a conditioning regimen that included busulfan and cyclophosphamide. Her disease relapsed ~ 49 months post-transplant. The family was known to have LiFraumeni syndrome. Their family history was notable for the father having leiomyosarcoma, papillary carcinoma of the thyroid, and Burkitt lymphoma. Three of the proband's four siblings also carried the TP53 mutation -one brother had rhabdomyosarcoma and subsequent therapy-related AML, another brother developed osteosarcoma and subsequent therapy-related MDS, and a third brother carrying the TP53 mutation remained cancer-free at last known follow-up. The paternal grandfather died of some form of lymphoma in his 50s. HIP01569 carried a heterozygous missense mutation in TP53 (c.626delGA [G245S]) which is a well-described mutation in the DNAbinding domain 30 . Li-Fraumeni syndrome is an autosomal dominant familial cancer predisposition syndrome associated with germline TP53 mutations. Leukemia, most commonly acute lymphoblastic leukemia (ALL) and less commonly AML, as well as reports of MDS or AML as secondary malignancies have been reported in Li-Fraumeni families [31] [32] [33] [34] . HIP01569 initially presented at 3 years-old with pro-B cell ALL and subsequently developed therapy-related MDS at 7 years of age. His family history was notable for a mother with breast cancer and a brother who passed away at the age of 12-years from rhabdomyosarcoma. GATA1  CTC1  ELANE  CBL  FANCA  AK2  RPL11  DKC1  G6PC3  CEBPA  FANCB  ANKRD26  RPL35a  NHP2  GFI1  ETV6  FANCC  ATM  RPL5  NOP10  HAX1  GATA2  FANCD1 (BRCA2 )  ATR  RPS10  RTEL1  JAGN1  PAX5  FANCD2  ATRX  RPS17  TERC  TCIRG1  RUNX1  FANCE  C15ORF41  RPS19  TERT  VPS45  TP53  FANCF  CDAN1  RPS24  TINF2  WAS  FANCG  LIG4  RPS26  WRAP53  FANCI  MPL  RPS7 FANCJ 
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